Clinical trials confirmed that upregulated VEGF was related to worse survival time, anti-VEGF treatment was efficient for inhibiting tumor angiogenesis and promoting tumor cell apoptosis, and anti-VEGF treatment could even reverse resistance to chemotherapy for patients with locoregionally advanced NPC (83, 84). The gene discussed is VEGFA; the disease is nasopharyngeal carcinoma.